Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OSU6162 in bipolar depression: an open-label, flexible dose study (OBID)
2020-001980-95Phase 2Active
- Sponsor
- University of Gothenburg
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of OSU-6162 in bipolar disorder (BD) and major depressive disorder (MDD), sponsored by University of Gothenburg. Primary endpoint: Change from baseline in MADRS total score. Started Dec 2020; status: active.
02
Drugs
OSU-6162
03
Conditions
bipolar disorder (BD)major depressive disorder (MDD)
Beyond the preview
Go deeper on 2020-001980-95.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001980-95.